Respiratory Infections

New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.

This man was the first person globally to have been diagnosed with influenza A(H5N2).

This is the second case in Michigan and it is confirmed in another farmworker who worked with infected cattle.

The flight originated from Germany then landed in Los Angeles and made a final stop in Fresno, California with the infected individual. CDC is aiding in tracking down people on these flights to find out exposure risks.

This genomic diagnostic tool aims to support diagnosis, particularly in immunocompromised patients by identifying pathogens associated with pneumonia and other lung infections.

A Michigan farmworker who had regular contact with livestock was confirmed to have contracted the virus.

Both the World Health Organization and FDA have now recommended this particular set of viruses be left off influenza vaccines for the 2024-2025 respiratory virus season. A new study points to further evidence of their extinction.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

Insights from Pranay Sinna MD on a multicenter prospective cohort study on household contacts.

Both the United Nations and World Health Organization (WHO) discussed the threat of H5N1, and its potential transmission to other mammals and humans.

The streptococcal pneumoniae urine antigen (SPUA) test was studied over the course of a year to determine if it provided any benefits in terms of diagnostic capability or aided in reducing empirical antibiotic use.

In these patient encounters, a deep cough as a symptom raised concerns around pneumonia and may have prompted prescription of antimicrobials, but did not show a resolution of symptoms sooner.

The origins of the recent H5N1 (avian flu) case in Texas remain unknown, but a researcher offers insights into transmission between animals and humans, the likelihood of more cases, vaccine availability, and treatment.

Community acquired pneumonia is often inappropriately diagnosed in hospital admissions, particularly among older adults with dementia, and can lead to in-hospital antibiotic-associated adverse events, such as Clostridioides difficile.

The case was confirmed in Texas and the person was in contact with cows. CDC says the risk for infection remains low.

A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.

Patients hospitalized for suspected community-acquired pneumonia received targeted treatment more quickly with PCR testing than with culture-based diagnostics.

Phase 2 study for the investigational antiviral, ZSP1273 (onradivir), demonstrated safety and efficacy in reducing the time to resolution of symptoms in a multicenter trial.

Group A streptococcal infections outbreak nearly doubles fatalities from the previous year.

Though more research is needed to determine reasons for the association, a study published in JAMA Network revealed the 2021-2022 influenza season was associated with a significantly higher household transmission risk compared to pre-pandemic seasons.

Results of a study by Yan Xie and colleagues highlight the severe impact of COVID-19, with higher death rates, increased risks of long-term complications, and greater infectivity compared to seasonal influenza.

In 43 of 154 school weeks, air samples were positive for influenza A virus (IAV) while SARS-CoV-2 was positive in air samples in 101 of 154 school weeks.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The company, RNAimmune, got the ok from the FDA for its vaccine, RV-1770.

The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.

The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.

Investigational 24-valent pneumococcal conjugate vaccine developed on cell-free protein synthesis platform is first to broaden coverage without reduced immunogenicity.

The unprecedented demand for the pediatric RSV immunization, nirsevimab-alip, has resulted in a dramatic uptake in production.

Amikacin inhaled once daily for 3 days reduced risk of developing ventilator-associated pneumonia in placebo-controlled trial in critically ill.

Last year was the fourth season to be classified as high severity since the 2009 influenza A(H1N1) pandemic.